Catalyst Pharmaceutical Partners (CPRX) PT Raised to $6.50 at Roth Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
- SanDisk upgraded at JPMorgan after investor day; shares climb
Catalyst Pharmaceutical Partners (CPRX) PT Raised to $9 at Oppenheimer Following 'Pre-Launch' Call
December 18, 2018 6:47 AM ESTOppenheimer analyst Leland Gershell raised the price target on Catalyst Pharmaceutical Partners (NASDAQ: CPRX) to $9.00 (from $6.00) while maintaining a Outperform rating following the company's "pre-launch" call last Thursday. Management provided sig detail around Firdapse's commercial strategy and announced pricing above expectations ($375K/yr).... More
